Drug repurposing represents a potentially rich source of new therapies because it involves the use of de-risked medicines that are already available to patients. The possible advantages of this approach include lower overall development costs and shorter development timelines, as well as economic and societal benefits for more sustainable healthcare systems in the long term. 

However, to crystallise these benefits significant challenges need to be addressed. These include overcoming regulatory hurdles, demonstrating utility and achieving the appropriate endpoint to allow best access for patients. 

To help charities and researchers devise their own strategies to repurpose drugs, LifeArc, supported by Pinsent Masons, is holding a seminar with a number of experts in the field to discuss issues such as intellectual property, regulation, commercial positioning and patient involvement.

Agenda

09:30

Attendees invited to join and set up

10:00

Welcome and introductions

LifeArc

10:05

Scene Setting - Repurposing existing drugs for Rare Diseases

Jo Pisani - LifeArc

10:20

The charity view

Anne Lennox - Myotubular Trust

10:35

Regulatory considerations

Dan O'Connor - MHRA

10:50

Intellectual Property and Patents

Nicole Jadeja - Pinsent Masons

11:05

The role of generics companies

Paul Fleming - BGMA

11:20

Break

11:30

Market access

Rob Whitmore - Roboleo & Co

11:45

Case studies - Tay-Sachs, Nieman Pick

Taylor Fields - Intrabio

12:00

Q&A and meeting close

 

Event date

10:00 - 12:30 GMT

Pinsent Masons Video

Speakers

Anne Lennox

Founding Trustee at Myotubular Trust

Dan O’Connor

Medical Assessor at MHRA

Jo Pisani

Trustee at LifeArc

Paul Fleming

Technical Director at BGMA

Rob Whitemore

Founder/Owner at Roboleo & Co Ltd

Taylor Fields

Senior Vice President at IntraBio